IDYA6:00 AMIDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business UpdateTrial Results • Phase 2/3ideayabio.com
IDYA6:00 AMIDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) ProgramTrial Results • Phase 2/3ideayabio.com
IDYA6:00 AMIDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal MelanomaTrial Results • Phase 2/3ideayabio.com